 For stage 3, subjects who are eligible to receive additional cycles of treatment and who elect to continue treatment will be scheduled within a week before the second expected menses - 2 days, following the off-drug interval. Subjects will receive 2 cycles of treatment separated by an off-drug interval ODI, after which they will be followed until menses has returned. 